Dr Reddy's shares: Should you buy the pharma stock as Q3 net profit rises 77%?1 min read . Updated: 27 Jan 2023, 07:51 AM IST
- Dr Reddy's Laboratories Ltd reported a bigger-than-expected 77% jump in third quarter ended December 2022 net profit
Drugmaker Dr Reddy's Laboratories Ltd reported a bigger-than-expected 77% jump in third quarter ended December 2022 net profit which rose to ₹ ₹1,247 crore as against ₹706.5 crore in the same quarter a year ago. Meanwhile, its revenue during the quarter was up by 27% to ₹6,770 crore as compared to ₹5,319.7 crore year-on-year (YoY). The company said that generic Revlimid, a multiple myeloma drug, which was launched in the US in September last year has been contributing to the topline meaningfully.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started
Select your Category